Effect of subsequence treatment after romosozumab in patietns with osteoporosis: open-label, randomised contorlled trial

Effect of subsequence treatment after romosozumab in patietns with osteoporosis: open-label, randomised contorlled trial - Effect of subsequence treatment after romosozumab in patietns with osteoporosis: open-label, randomised contorlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040132

Enrollment

165

Registered

2020-04-11

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Bisphosphonate group Denosumab group Teriparatide group Sub-group:Bisphosphonate(patients previously treated with PTH). An additional target sample size of 15 patients was set for this subgroup, apar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who finished 12 months of romosozumab treatment and plan to subsequence treatment. Written informed consent is needed to participate this study.

Exclusion criteria

Exclusion criteria: 1.Those who have history of cancer. 2.Patients with severe renal dysfunction or those receiving dialysis 3. Those who have hypocalcemia 4.Patients who is going to have an operation. 5.Patients who the research director judge inappropriate as a subject 6.For pregnant women or women who are nursing 7. Nonambulatory patients.

Design outcomes

Primary

Measure	Time frame
Bone strength	—

Secondary

Measure	Time frame
Bone mineral density, Bone turnover markers, Fracture events	—

Countries

Japan

Contacts

Public ContactKOJI ISHIKAWA

Showa University School of Medicine Department of Orthopaedics Surgery, Showa University School of Medicine

koji.ishikawa@med.showa-u.ac.jp0337848543

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026